Samanta R. Zanetti

Bizkaia Technology Park
Derio, PV, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

Journal: Blood

Published: May 16, 2024

NEDDylation Regulates CD8+ T-cell Metabolism and Antitumor Immunity.

NEDDylation Regulates CD8+ T-cell Metabolism and Antitumor Immunity.

Journal: Cancer immunology research

Published: March 25, 2024

Factor-inhibiting HIF (FIH) promotes lung cancer progression.

Factor-inhibiting HIF (FIH) promotes lung cancer progression.

Journal: JCI insight

Published: December 20, 2022

TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia.

TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia.

Journal: Haematologica

Published: November 22, 2022

A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants.

A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants.

Journal: Frontiers in immunology

Published: August 08, 2022

Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.

Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.

Journal: International review of cell and molecular biology

Published: July 07, 2022

CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.

CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.

Journal: Blood

Published: November 17, 2021

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.

Journal: Cancer immunology research

Published: October 07, 2021

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: January 12, 2021

Enforced sialyl-Lewis-X (sLeX) display in E-selectin ligands by exofucosylation is dispensable for CD19-CAR T-cell activity and bone marrow homing.

Enforced sialyl-Lewis-X (sLeX) display in E-selectin ligands by exofucosylation is dispensable for CD19-CAR T-cell activity and bone marrow homing.

Journal: Clinical and translational medicine

Published: September 22, 2020

Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity.

Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity.

Journal: Journal for immunotherapy of cancer

Published: August 08, 2020

Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.

Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.

Journal: Journal for immunotherapy of cancer

Published: June 22, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026